Clinical Pharmacology in Drug Development, Volume 14, Issue 8, Page 605-613, August 2025.Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez +5 more
wiley +1 more source
Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach
HeliyonIntroduction: CYP2C19 is a highly polymorphic gene responsible for metabolizing commonly used drugs. CYP2C19*2,*3 (loss of activity alleles) and *17 (increased activity allele) are the principal alleles included in clinical guidelines, however their ...
Alba Alonso Llorente +6 more
doaj
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 438-448, August 2025.In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen +12 more
wiley +1 more source
From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Frontiers in PharmacologyThe CYP2C19 gene is frequently included in different pharmacogenomic panels tested in clinical practice, due to its involvement in the metabolism of a myriad of frequently prescribed medications.
Qamar Shubbar +8 more
doaj +1 more source
A study of associations of polymorphic variants of cytochrome P-450 system genes and multi-drug resistance gene with the development of druginduced hyperprolactinemia in patients with schizophrenia [PDF]
, 2017 The detection of clinical and biological associations in different alleles and genotypes allows to create the fundament for development methods, which help to identify risk of side-effects in patients with schizophrenia, who received long-term ...
Воронина, Е. Н. +1 more
core
Estimating the Frequency of False‐Negative Pharmacogenetic Test Results by Self‐Reported Ancestry
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 331-336, August 2025.Concerns about the applicability of pharmacogenetic (PGx) testing across diverse ancestry groups have risen from the underrepresentation of non‐European populations in PGx research. Current PGx panels may fail to detect relevant variants in non‐European populations, increasing the likelihood of false‐negative results.
Weng‐Sam Siu +7 more
wiley +1 more source
MOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPY
Acta Biomedica Scientifica, 2012 The targets of application of antiaggregant therapy by clopidogrel and the factors that influence its outcome were presented, in this review. Special attention was given to the application of personalized, approach for the optimization of clopidogrel ...
N. YU. Knauer, G. I. Lifshits
doaj
CYP2C19*17 Polymorphisms And Platelet Aggregation In Coronary Artery Disease Patients With Clopidgrel [PDF]
, 2017 Background: Clopidogrel is the alternative therapy for patients with Coronary Artery Disease (CAD) that couldn’t use Aspirin as antiplatelet. There’s some factors that contribute to clopidogrel effectiveness, such as obesity, Diabetes Mellitus, Smoking,
Ananda, Yuki +2 more
core
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19 [PDF]
, 2002 Joo‐Youn Cho +5 more
openalex +1 more source